July 8, 2016
SKEL associate researcher and BioHIT member, Anastasios Nentidis will present “Drug Repositioning: Existing approaches and applicability for Duchenne Muscular Dystrophy” on Thursday 18/7.
Abstract
Duchenne Muscular Dystrophy (DMD) is a severe progressive muscle-wasting disease caused by the absence of a functional dystrophin protein. Currently, no cure is available for DMD and among treatment options, only the use of corticosteroids has shown a clear beneficial effect. As novel drug development is a long procedure, identifying repositioning opportunities for existing drugs in DMD treatment, emerges as an appealing alternative. This is an introduction in existing approaches used for Drug Repositioning, with an emphasis on computational ones, under the perspective of applicability for DMD.